PAG
HQL

Private Advisor Group’s abrdn Life Sciences Investors HQL Stock Holding History

Private Advisor Group’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$468K Sell
23,405
-53,575
-70% -$947K ﹤0.01% 1840
2026
Q1 		$1.25M Buy
76,980
+12,753
+20% +$213K 0.01% 1292
2025
Q4 		$1.08M Buy
64,227
+539
+0.8% +$9.06K 0.01% 1368
2025
Q3 		$988K Buy
63,688
+12,356
+24% +$169K ﹤0.01% 1377
2025
Q2 		$658K Buy
51,332
+28,257
+122% +$348K ﹤0.01% 1539
2025
Q1 		$293K Buy
23,075
+1,097
+5% +$14.9K ﹤0.01% 1890
2024
Q4 		$288K Sell
21,978
-4,351
-17% -$62.8K ﹤0.01% 1880
2024
Q3 		$397K Sell
26,329
-924
-3% -$14K ﹤0.01% 1752
2024
Q2 		$386K Sell
27,253
-4,510
-14% -$61K ﹤0.01% 1714
2024
Q1 		$433K Sell
31,763
-2,411
-7% -$33.4K ﹤0.01% 1608
2023
Q4 		$460K Sell
34,174
-872
-2% -$10.7K ﹤0.01% 1531
2023
Q3 		$435K Buy
35,046
+15,459
+79% +$203K ﹤0.01% 1439
2023
Q2 		$265K Hold
19,587
– – ﹤0.01% 1701
2023
Q1 		$273K Hold
19,587
– – ﹤0.01% 1633
2022
Q4 		$278 Sell
19,587
-4,942
-20% -$71.6K ﹤0.01% 1475
2022
Q3 		$335K Buy
24,529
+3,921
+19% +$58.6K ﹤0.01% 1413
2022
Q2 		$293K Buy
20,608
+498
+2% +$7.52K ﹤0.01% 1659
2022
Q1 		$333K Sell
20,110
-752
-4% -$12.9K ﹤0.01% 1620
2021
Q4 		$401K Sell
20,862
-3,260
-14% -$65.6K ﹤0.01% 1573
2021
Q3 		$502K Buy
+24,122
New +$516K ﹤0.01% 1509
2019
Q4 		– Sell
-84,142
Closed -$1.36M – 1673
2019
Q3 		$1.36M Buy
84,142
+39,581
+89% +$634K 0.02% 669
2019
Q2 		$751K Buy
44,561
+3,185
+8% +$52.5K 0.01% 856
2019
Q1 		$709K Buy
41,376
+2,322
+6% +$40.1K 0.01% 824
2018
Q4 		$590K Buy
39,054
+4,201
+12% +$74K 0.01% 786
2018
Q3 		$712K Buy
34,853
+3,913
+13% +$77.8K 0.01% 834
2018
Q2 		$581K Buy
30,940
+9,173
+42% +$173K 0.01% 690
2018
Q1 		$418K Buy
+21,767
New +$436K 0.02% 740
2016
Q4 		– Sell
-15,653
Closed -$290K – 1307
2016
Q3 		$290K Buy
15,653
+624
+4% +$11.8K 0.01% 842
2016
Q2 		$268K Sell
15,029
-806
-5% -$14.9K 0.01% 865
2016
Q1 		$284K Buy
15,835
+1,556
+11% +$28.2K 0.01% 786
2015
Q4 		$338K Buy
14,279
+535
+4% +$13.3K 0.02% 745
2015
Q3 		$309K Buy
13,744
+6,492
+90% +$182K 0.02% 723
2015
Q2 		$205K Buy
+7,252
New +$201K 0.01% 943

Other funds holding HQL

FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
UPS
UHLMANN PRICE SECURITIES Skokie, Illinois $2.68B AUM 149.5% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
ZCP
Z3 Capital Partners Richmond, Virginia $476M AUM
SI
Stephens Inc Little Rock, Arkansas $8.93B AUM 25.13% 1-Year Est. Return
CEFA
Closed-End Fund Advisors Richmond, Virginia $102M AUM
KAS
KPP Advisory Services Louisville, Kentucky $791M AUM 28.5% 1-Year Est. Return
PFO
PMG Family Office Plano, Texas $109M AUM 15.87% 1-Year Est. Return

Private Advisor Group's HQL Position: Q2 2026 in Review

Private Advisor Group reduced its abrdn Life Sciences Investors (HQL) stake by 70% in Q2 2026, selling an estimated $947K and leaving 23,405 shares worth $468K. The position accounts for ﹤0.01% of the portfolio, ranked #1840.

Private Advisor Group first reported a position in HQL in Q2 2015 and has held it in 33 quarters since. The position peaked at $1.36M in Q3 2019. 35 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

  • Private Advisor Group held 23,405 shares of abrdn Life Sciences Investors worth $468K as of Q2 2026.
  • Private Advisor Group sold 53,575 abrdn Life Sciences Investors shares in Q2 2026, an estimated $947K.
  • abrdn Life Sciences Investors made up ﹤0.01% of Private Advisor Group's portfolio in Q2 2026, its #1840 holding.
  • Private Advisor Group first reported a position in abrdn Life Sciences Investors in Q2 2015 and has held it in 33 quarters since.
  • Private Advisor Group's abrdn Life Sciences Investors position peaked at $1.36M in Q3 2019.
  • 35 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.